Further validation of key results (LOH transitions, PARP1 amplifications, BRCA2 isoform switching) in an independent cohort of paired primary and recurrent BRCA1/2 mutation-associated breast and ovarian tumors will be important. This evidence concerns the gene BRCA1 and ovarian neoplasm.